Literature DB >> 10429242

Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity.

G Adlakha-Hutcheon1, M B Bally, C R Shew, T D Madden.   

Abstract

Programmable fusogenic vesicles (PFVs) are lipid-based drug-delivery systems that exhibit time-dependent destabilization. The rate at which this destabilization occurs is determined by the exchange rate of a bilayer-stabilizing component, polyethylene glycol-phosphatidylethanolamine (PEG-PE) from the vesicle surface. This exchange rate is controlled, in turn, by the acyl chain composition of the PEG-PE. We describe in vitro and in vivo studies using PFVs as delivery vehicles for the anticancer drug mitoxantrone. We demonstrate that the PEG-PE acyl composition determined the rate at which PFVs are eliminated from plasma after intravenous administration, and the rate of mitoxantrone leakage from PFV. The nature of the PEG-PE component also determined the antitumor efficacy of mitoxantrone-loaded PFV in murine and human in murine and human xenograft tumor models. Increased circulation time and improved activity were obtained for PFV containing PEG-PE with an 18-carbon acyl chain length, as a result of slower vesicle destabilization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10429242     DOI: 10.1038/11710

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  16 in total

1.  Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes.

Authors:  Sang-Min Lee; SonBinh T Nguyen
Journal:  Macromolecules       Date:  2013-11-27       Impact factor: 5.985

Review 2.  Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors:  Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Adv Drug Deliv Rev       Date:  2011-05-03       Impact factor: 15.470

Review 3.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

4.  Acute and subchronic (28-day) oral toxicity study in rats fed with novel surfactants.

Authors:  Ranjit Madhukar Bidhe; Sangita Ghosh
Journal:  AAPS PharmSci       Date:  2004-04-07

5.  Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics.

Authors:  Junhwa Shin; Pochi Shum; Jessica Grey; Shin-ichi Fujiwara; Guarov S Malhotra; Andres González-Bonet; Seok-Hee Hyun; Elaine Moase; Theresa M Allen; David H Thompson
Journal:  Mol Pharm       Date:  2012-10-03       Impact factor: 4.939

6.  Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate.

Authors:  Jeremy A Boomer; Marquita M Qualls; H Dorota Inerowicz; Robert H Haynes; V Srilakshmi Patri; Jong-Mok Kim; David H Thompson
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

7.  Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide.

Authors:  Hongxia Zhao; Patricia M Dubielecka; Tim Söderlund; Paavo K J Kinnunen
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

8.  Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.

Authors:  Qiang Hu; Marcel B Bally; Thomas D Madden
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

9.  Porphyrin-phospholipid liposomes with tunable leakiness.

Authors:  Dandan Luo; Kevin A Carter; Aida Razi; Jumin Geng; Shuai Shao; Cuiyan Lin; Joaquin Ortega; Jonathan F Lovell
Journal:  J Control Release       Date:  2015-11-11       Impact factor: 9.776

Review 10.  Sheddable coatings for long-circulating nanoparticles.

Authors:  Birgit Romberg; Wim E Hennink; Gert Storm
Journal:  Pharm Res       Date:  2007-06-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.